Invesco Ltd. Increases Stake in Haemonetics Corporation $HAE

Key Points

• Invesco Ltd. has increased its stake in Haemonetics Corporation by 10.1% during the first quarter, now owning approximately 0.21% of the company valued at $6.71 million.
• Analysts have mixed views on Haemonetics, with price targets revised down from previous highs; Barrington Research lowered its target from $95.00 to $86.00, while JPMorgan also cut its target from $85.00 to $62.00.
• Haemonetics reported earnings of $1.10 EPS for the most recent quarter, exceeding expectations and setting a FY 2026 guidance of $4.70 to $5.00 EPS.

Invesco Ltd. lifted its stake in Haemonetics Corporation (NYSE:HAE - Free Report) by 10.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 105,645 shares of the medical instruments supplier's stock after purchasing an additional 9,654 shares during the period. Invesco Ltd. owned about 0.21% of Haemonetics worth $6,714,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Global Alpha Capital Management Ltd. grew its holdings in shares of Haemonetics by 61.1% in the first quarter. Global Alpha Capital Management Ltd. now owns 27,553 shares of the medical instruments supplier's stock worth $1,751,000 after purchasing an additional 10,452 shares during the last quarter. Zions Bancorporation National Association UT purchased a new stake in Haemonetics in the first quarter worth about $2,744,000. Citigroup Inc. lifted its stake in Haemonetics by 87.3% in the first quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier's stock worth $39,755,000 after acquiring an additional 291,574 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Haemonetics by 0.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 556,027 shares of the medical instruments supplier's stock worth $35,336,000 after acquiring an additional 4,834 shares during the period. Finally, Cary Street Partners Financial LLC purchased a new stake in Haemonetics in the first quarter worth about $1,082,000. 99.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on HAE shares. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $62.00 price objective (down from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Needham & Company LLC reaffirmed a "buy" rating and issued a $68.00 price objective (down from $84.00) on shares of Haemonetics in a research note on Thursday, August 7th. Baird R W raised shares of Haemonetics to a "strong-buy" rating in a research note on Wednesday, June 25th. Wall Street Zen lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Finally, Mizuho lowered their price objective on shares of Haemonetics from $90.00 to $70.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $85.18.

Haemonetics Stock Up 0.5%

Shares of HAE stock traded up $0.29 during mid-day trading on Friday, hitting $54.63. 826,354 shares of the stock traded hands, compared to its average volume of 1,324,994. The stock has a market cap of $2.63 billion, a P/E ratio of 16.71, a P/E/G ratio of 1.01 and a beta of 0.40. The stock's fifty day moving average is $67.99 and its two-hundred day moving average is $66.07. Haemonetics Corporation has a 52-week low of $50.68 and a 52-week high of $94.99. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, beating the consensus estimate of $1.01 by $0.09. The business had revenue of $321.39 million during the quarter, compared to analyst estimates of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company's quarterly revenue was down 4.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. Equities analysts predict that Haemonetics Corporation will post 4.55 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.